The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.

L. Herszényi, M. Plebani, R. Cardin, P. Carraro, M. De Paoli, G. Roveroni, R. Naccarato, F. Farinati

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

BACKGROUND: It has been proposed that the serine protease urokinase-type plasminogen activator (UPA) and its inhibitor type-1 (PAI-1) may play an important part in cancer spread and metastasis. AIMS OF THE STUDY: 1. To determine the UPA, PAI-1 antigen levels in gastric cancer (GC) and in normal gastric mucosa far from the tumor (NORM). 2. To evaluate changes related to the presence of metastasis, tumor differentiation (grading) and histotype. PATIENTS AND METHODS: Samples of tumor and of normal mucosa were obtained from 25 GC patients undergoing surgery (17 males, 8 females, mean age 62, range 31-84). Antigen concentrations were measured using the ELISA method. RESULTS: Significantly higher UPA and PAI-1 antigen levels were found: 1. in GC vs. NORM tissue; 2. in patients with poorly and moderately differentiated GC vs. well-differentiated GC. UPA was significantly higher in GC with vs. without metastasis. PAI-1 was also higher, though not significantly so, in GC with metastasis than in GC without metastasis. CONCLUSION: Our results confirm that the serine protease UPA and its inhibitor PAI-1 play an important role in GC progression. Considering the higher protease levels detected in GC with metastases and poorer differentiation, UPA and PAI-1 might be useful for identifying gastric cancer patients with a poor prognosis.

Original languageEnglish
Pages (from-to)213-221
Number of pages9
JournalActa Physiologica Hungarica
Volume83
Issue number3
Publication statusPublished - 1995

Fingerprint

Plasminogen Inactivators
Plasminogen Activator Inhibitor 1
Urokinase-Type Plasminogen Activator
Stomach Neoplasms
Neoplasm Metastasis
Serine Proteases
Antigens
Neoplasms
Neoplasm Grading
Gastric Mucosa
Mucous Membrane
Peptide Hydrolases
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Physiology

Cite this

Herszényi, L., Plebani, M., Cardin, R., Carraro, P., De Paoli, M., Roveroni, G., ... Farinati, F. (1995). The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer. Acta Physiologica Hungarica, 83(3), 213-221.

The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer. / Herszényi, L.; Plebani, M.; Cardin, R.; Carraro, P.; De Paoli, M.; Roveroni, G.; Naccarato, R.; Farinati, F.

In: Acta Physiologica Hungarica, Vol. 83, No. 3, 1995, p. 213-221.

Research output: Contribution to journalArticle

Herszényi, L, Plebani, M, Cardin, R, Carraro, P, De Paoli, M, Roveroni, G, Naccarato, R & Farinati, F 1995, 'The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.', Acta Physiologica Hungarica, vol. 83, no. 3, pp. 213-221.
Herszényi, L. ; Plebani, M. ; Cardin, R. ; Carraro, P. ; De Paoli, M. ; Roveroni, G. ; Naccarato, R. ; Farinati, F. / The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer. In: Acta Physiologica Hungarica. 1995 ; Vol. 83, No. 3. pp. 213-221.
@article{8d1bd6d4737e4f4ea2a2714922860bcc,
title = "The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.",
abstract = "BACKGROUND: It has been proposed that the serine protease urokinase-type plasminogen activator (UPA) and its inhibitor type-1 (PAI-1) may play an important part in cancer spread and metastasis. AIMS OF THE STUDY: 1. To determine the UPA, PAI-1 antigen levels in gastric cancer (GC) and in normal gastric mucosa far from the tumor (NORM). 2. To evaluate changes related to the presence of metastasis, tumor differentiation (grading) and histotype. PATIENTS AND METHODS: Samples of tumor and of normal mucosa were obtained from 25 GC patients undergoing surgery (17 males, 8 females, mean age 62, range 31-84). Antigen concentrations were measured using the ELISA method. RESULTS: Significantly higher UPA and PAI-1 antigen levels were found: 1. in GC vs. NORM tissue; 2. in patients with poorly and moderately differentiated GC vs. well-differentiated GC. UPA was significantly higher in GC with vs. without metastasis. PAI-1 was also higher, though not significantly so, in GC with metastasis than in GC without metastasis. CONCLUSION: Our results confirm that the serine protease UPA and its inhibitor PAI-1 play an important role in GC progression. Considering the higher protease levels detected in GC with metastases and poorer differentiation, UPA and PAI-1 might be useful for identifying gastric cancer patients with a poor prognosis.",
author = "L. Hersz{\'e}nyi and M. Plebani and R. Cardin and P. Carraro and {De Paoli}, M. and G. Roveroni and R. Naccarato and F. Farinati",
year = "1995",
language = "English",
volume = "83",
pages = "213--221",
journal = "Physiology International",
issn = "2498-602X",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.

AU - Herszényi, L.

AU - Plebani, M.

AU - Cardin, R.

AU - Carraro, P.

AU - De Paoli, M.

AU - Roveroni, G.

AU - Naccarato, R.

AU - Farinati, F.

PY - 1995

Y1 - 1995

N2 - BACKGROUND: It has been proposed that the serine protease urokinase-type plasminogen activator (UPA) and its inhibitor type-1 (PAI-1) may play an important part in cancer spread and metastasis. AIMS OF THE STUDY: 1. To determine the UPA, PAI-1 antigen levels in gastric cancer (GC) and in normal gastric mucosa far from the tumor (NORM). 2. To evaluate changes related to the presence of metastasis, tumor differentiation (grading) and histotype. PATIENTS AND METHODS: Samples of tumor and of normal mucosa were obtained from 25 GC patients undergoing surgery (17 males, 8 females, mean age 62, range 31-84). Antigen concentrations were measured using the ELISA method. RESULTS: Significantly higher UPA and PAI-1 antigen levels were found: 1. in GC vs. NORM tissue; 2. in patients with poorly and moderately differentiated GC vs. well-differentiated GC. UPA was significantly higher in GC with vs. without metastasis. PAI-1 was also higher, though not significantly so, in GC with metastasis than in GC without metastasis. CONCLUSION: Our results confirm that the serine protease UPA and its inhibitor PAI-1 play an important role in GC progression. Considering the higher protease levels detected in GC with metastases and poorer differentiation, UPA and PAI-1 might be useful for identifying gastric cancer patients with a poor prognosis.

AB - BACKGROUND: It has been proposed that the serine protease urokinase-type plasminogen activator (UPA) and its inhibitor type-1 (PAI-1) may play an important part in cancer spread and metastasis. AIMS OF THE STUDY: 1. To determine the UPA, PAI-1 antigen levels in gastric cancer (GC) and in normal gastric mucosa far from the tumor (NORM). 2. To evaluate changes related to the presence of metastasis, tumor differentiation (grading) and histotype. PATIENTS AND METHODS: Samples of tumor and of normal mucosa were obtained from 25 GC patients undergoing surgery (17 males, 8 females, mean age 62, range 31-84). Antigen concentrations were measured using the ELISA method. RESULTS: Significantly higher UPA and PAI-1 antigen levels were found: 1. in GC vs. NORM tissue; 2. in patients with poorly and moderately differentiated GC vs. well-differentiated GC. UPA was significantly higher in GC with vs. without metastasis. PAI-1 was also higher, though not significantly so, in GC with metastasis than in GC without metastasis. CONCLUSION: Our results confirm that the serine protease UPA and its inhibitor PAI-1 play an important role in GC progression. Considering the higher protease levels detected in GC with metastases and poorer differentiation, UPA and PAI-1 might be useful for identifying gastric cancer patients with a poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=0029433840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029433840&partnerID=8YFLogxK

M3 - Article

C2 - 8852646

AN - SCOPUS:0029433840

VL - 83

SP - 213

EP - 221

JO - Physiology International

JF - Physiology International

SN - 2498-602X

IS - 3

ER -